Curriculum Vitae

Isaac Eliaz, MD, MS, LAc

Amitabha Medical Clinic & Healing Center
398 Tesconi Ct., Santa Rosa CA 95401, 707-542-5900

Isaac Eliaz, MD, MS, LAc has been an expert in the field of integrative medicine since the early 1980s, with a focus on cancer, immune health, detoxification, and chronic conditions. He is a respected researcher, clinician, bestselling author, keynote speaker, and a life-long student and practitioner of meditation. 

Dr. Eliaz is regarded as a leading authority in the field of galectin-3 research and the use of galectin-3 antagonists and related treatments for cancer and complex chronic conditions. A recipient of multiple NIH grants, Dr. Eliaz is currently developing a medical device for the removal of circulating galectin-3, proposed to provide a novel treatment for conditions such as sepsis, Acute Kidney Injury (AKI), and chronic kidney disease, for which no effective therapies exist. Preliminary research results suggest this device has broad clinical potential for the treatment of acute and chronic inflammatory and fibrotic conditions, as well as in cancer immunotherapy.

With 30+ years of clinical training and experience, Dr. Isaac Eliaz is a highly skilled practitioner with a unique, holistic approach to health and healing. His extensive background in diverse medical systems including Western medicine and translational research, Traditional Asian medicine, and complementary modalities, has earned him recognition as an expert innovator in the integrative treatment of complex, chronic conditions. In 2001, he founded Amitabha Medical Clinic in Santa Rosa, CA, where patients come from around the world to receive leading-edge, patient-centered treatment and care.

Through his work at Amitabha Clinic, Dr. Eliaz is recognized for pioneering the application of therapeutic apheresis in the management of cancer and inflammatory diseases in the US. As a leading authority on apheresis treatment, Dr. Eliaz has provided significant contributions and new applications to this field.

As part of his commitment to the advancement of integrative medicine, Dr. Eliaz partners with renowned research institutes including Harvard, Columbia, and others, to co-author peer-reviewed papers on therapies for immune enhancement, heavy metal toxicity, cancer prevention and treatment, and other areas. Many of Dr. Eliaz’s innovations have been validated in peer-reviewed literature, and he regularly lectures at international medical conferences and scientific meetings on the use of these and other therapies for cancer and chronic diseases.

1991 Master of Science in Traditional Chinese Medicine, American College of Traditional Chinese Medicine, San Francisco, CA
1988-1989 Graduate studies in Clinical Herbology, Hebrew University of Jerusalem, Faculty of Agriculture, External Division
1987-1988 Internship at Wolfson Hospital, Holon, Israel
1986 Doctor of Medicine, Sackler Medical School, Tel Aviv University, Israel
1980-1986 Full-time academic studies at Sackler Medical School
2015 University of Virginia – Summer Tibetan language intensive
2011 Fellowship in Integrative Cancer Therapies – The American Academy of Anti-Aging Medicine
1997-1999 Post Graduate Study in Chinese Language – Private Tutorial
1997 Elementary Chinese – University of California, Berkeley
1995-2000 Studies of the Ancient and Classical Texts of Chinese Medicine, Private Study Group, San Francisco, California
1986-1988 Chinese Medicine – Personal Tutorial with Dr. J. M. Eyssalet
1986-1988 Acupuncture, Tel Aviv, Israel
1983-1985 Shiatsu and Japanese Manipulation Therapy
1983 Yoga Teaching Certification Program, Bror Hail, Israel
1974-1975 Taekwondo, Black belt, Seoul, Korea
2005 Licensed Homeopathic Medical Physician, State of Arizona
2000 Licensed Physician, State of California
2000 U.S. Medical Licensing Examination, Part III, CA
1999-2000 U.S. Medical Residency in Family Practice Medicine, Modesto, CA
1994-1995 U.S. Medical Licensing Examination, Parts I and II, CA
1992 Licensed Acupuncturist, State of California
1991 Diplomat in Acupuncture, National Commission for the Certification of Acupuncturists
1988 Licensed Physician, Israel
2001-Present Private Practice in Integrative Medicine – Amitabha Medical Clinic and Healing Center, Santa Rosa, CA.
2000-2001 Private Practice in Medicine – Lucas Valley Clinic, San Rafael, CA.
1997-1999 Director of Lucas Valley Clinic, San Rafael, CA. Integrated treatment modalities including traditional Chinese medicine, acupuncture, and nutrition.
1993-1997 Private Practice in Acupuncture – Preventive Medicine Center of Marin, San Rafael, CA
1992-1993 Private Practice in Acupuncture, Sonoma and Berkeley, CA
1988-1999 Private Practice in Medicine, Israel
1989-present Research and development of modified citrus pectin and other nutraceuticals and nutritional supplements, including preparations for prostate, cellular, immune, metabolic and other areas of health. Designed and implemented preclinical and clinical trials that evaluated the efficacy of these preparations. Research published in peer review journals, presented in multiple medical conferences, and written in peer review text books.Research collaborations include the following research and academic institutions: Harvard University/Massachusetts General Hospital, Boston University/Boston Medical Center/NIH, Cancer Treatment Centers of America, Columbia University, Hull University (UK), Johns Hopkins University, Mayo Clinic, MD Anderson Cancer Center, University of Texas, Meir Medical Center (Israel), Nanjing University (China), Technion-Israel Institute of Technology (Israel), Tel Aviv University (Israel), Tufts University, USDA-ARS, University of California, Davis, University of Groningen (Netherlands), University of Indiana, University of Kansas. A primary focus has been research and development of the plant-based galectin-3 inhibitor PectaSol-C-Modified Citrus Pectin (MCP). Dr. Eliaz is recognized internationally as a foremost expert on galectin-3 and the use of MCP in clinical practice. Over 40 scientific papers have been published evaluating the use of PectaSol-C, demonstrating its ability to inhibit inflammation and fibrosis in multiple organs and inhibit cancer proliferation, angiogenesis, adhesion and metastasis. Currently there are two active clinical trials in process evaluating the use of MCP in specific patient populations as follows: Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA https://clinicaltrials.gov/ct2/show/NCT01681823 Galectin-3 Blockade in Patients With High Blood Pressure https://clinicaltrials.gov/ct2/show/NCT01960946
  1. Eliaz I, Weil E, Schwarzbach J, Wilk B. Modified Citrus Pectin / Alginate Dietary Supplement Increased Fecal Excretion of Uranium: A Family. Altern Ther Health Med. 2019;25(4):20-24.
  2. Eliaz I, and Sliva D. BreastDefend Enhances Effect of Tamoxifen in Estrogen Receptor-positive Human Breast Cancer in Vitro and in Vivo. International Conference on Cancer Research 2019. London, UK. June 2019.
  3. Eliaz I. Letter to the Editor: Not all modified citrus pectins are the same: size does matter. Am J Physiol Heart Circ Physiol. 2019 May 1;316(5):H1232-H1233.
  4. Dresler H, Frenkel MA, Peer A, Rosenbaum E, Margel D, Sarid DL, Neiman V, Gottfried M, NMaimon N, Leibovitch I, Keizman D, Eliaz I. Effect of PectaSol-C Modified Citrus Pectin Treatment on PSA Dynamics in Non-Metastatic Biochemically Relapsed Prostate Cancer Patients: Results of a Prospective Phase II Study. Poster Session:10th European Multidisciplinary Congress on Urological Cancers. Amsterdam, Netherlands. Nov. 2018.
  5. Eliaz I. Effect of Modified Citrus Pectin Treatment on Psa Dynamics In Non-Metastatic Biochemically Relapsed Prostate Cancer Patients: Interim Results of a Phase IIb Study – The 8th International Conference of the Society for Integrative Oncology. Cleveland, OH. Nov. 2018.
  6. Navarro-Alvarez N, Goncalves B, Andrews A, Wang Z, Wang, Z, Harrington E, Jigesh Shah J, Weil E, Wilk B, Sachs DH, Eliaz I, Huang CA. The effects of galectin-3 depletion apheresis on induced skin inflammation in a porcine model. J Clin Apher. 2018 Aug;33(4):486-493.
  7. Conti S, Vexler A, Hagoel L, Corn BW, Nir Honig N, Shtraus N, Meir Y, Ron I, Eliaz E, Lev-Aria S. Modified citrus pectin as a potential sensitizer for radiotherapy in prostate cancer phytomedicine. Integr Cancer Ther. 2018 Jul 25:1534735418790382.
  8. Keizman D, Frenkel MA, Peer A, Rosenbaum E, Margel D, Sarid DL, Neiman V, Gottfried M, Maimon N, Leibovitch I, Dresler H, Eliaz I. Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): Results of the interim analysis of a prospective phase II study. Poster Session: 2018 Genitourinary Cancers Symposium J Clin Oncol 36, 2018 (suppl 6S; abstr 14)
  9. Eliaz I, Weil E, Wilk B. Improvements in self-reported lower urinary tract symptoms with prostate health supplement. Altern Ther Health Med. 2018 Feb 10. pii: AT5449.
  10. Eliaz I, Pail A, Navarro-Alvarez N, Wang Z, Eliaz A, Weil E, Wilk B, Sachs DH, Huang CA. Methods for the detection and serum depletion of porcine galectin-3. J Clin Apher. 2018 Dec;39(12):1885-1893.
  11. Cheng S, Castillo V, Welty W, Alvarado M, Eliaz I, Temm CJ, Sandusky GE, Sliva D. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo. BMC Complement Altern Med. 2017 Feb; 17: 115.
  12. Ramachandran C, Wilk BJ, Melnick SJ, Eliaz I. Synergistic antioxidant and anti-inflammatory effects between modified citrus pectin and honokiol. eCAM. 2017;2017:8379843.
  13. Ramachandran C, Wilk BJ, Melnick SJ, Eliaz I. Antioxidant and anti-inflammatory effects of a polybotanical multinutrient formula. BMR Phytomedicine. 2017 Mar;3(1):1-10.
  14. Cheng S, Castillo V, Welty M, Eliaz I, Sliva D. Honokiol inhibits migration of renal cell carcinoma through activation of RhoA/ROCK/MLC signaling pathway. Inter J Oncol. 2016 September. Prepublished.
  15. Zhang Q, Zhao W, Ye C, Zhuang J, Chang C, Li Y, Huang X, Shen L, Li Y, Cui Y, Song J, Shen B, Eliaz I, Huang R, Ying H, Guo H, Yan J. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis. Oncotarget. 2015 Nov 10;6(35):37335-48.
  16. Eliaz I, Weil E, Dutton J, McCalley AE, Nolte B, Moriarty PM. Lipoprotein apheresis reduces circulating galectin-3 in humans. J Clin Apheresis. 2016 Aug;31(4):388-92.
  17. Cheng S, Swanson K, Eliaz I, McClintick J, Terry C, Sandusky GE, Sliva D. Pachymic acid inhibits growth and induces apoptosis of pancreatic cancer in vitro and in vivo by targeting ER stress. PLoS One. 2015 2015 Apr 27;10(4):e0122270.
  18. Cheng S, Castillo V, Eliaz I Sliva D. Honokiol suppresses metastasis of renal cell carcinoma by targeting KISS1/KISS1R signaling. Intern. J Oncol. 2015 Apr; doi: 10.3892/ijo.2015.2950.
  19. Cheng S, Alvarado M, Loganathan J, Castillo V, Sandusky G, Eliaz I, Sliva D. BreastDefend enhances the effects of tamoxifen in estrogen receptor-positive human breast cancer in vitro and animal models in vivo. Poster Session: American Association for Cancer Research. Philadelphia, PA. Apr. 2015.
  20. Conti S, Vexler A, Eliaz I, Koren B, Honig N, Shtraus N, Meir Y, Ilan R, Lev-Ari S. Combined effect of modified citrus pectin and ionizing radiation on survival and metastatic activity of prostate cancer cells. Poster Session: American Association for Cancer Research. Philadelphia, PA. Apr. 2015.
  21. Zhang Q, Zhao W, Ye C, Chang C, Li Y, Huang X, Zhuang J, Song J, Cui Y, Shen B, Eliaz I, Huang R, Ying H, Yan J, Guo H. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis. Poster Session: American Association for Cancer Research. Philadelphia, PA. Apr. 2015.
  22. Khan A, Marier D, Marsden E, Andrews D, Eliaz I. A novel form of dichloroacetate therapy for patients with advanced cancer: a report of 3 cases. Altern Ther Health Med. 2014 Oct;20 Suppl 2:2-8.
  23. Eliaz I, Weil, E. Clinical benefit in patients with solid tumors treated with intravenous honokiol: A prospective pilot study. Poster Session: 11th International Conference of the Society for Integrative Oncology. Houston, TX. Oct. 2014.
  24. Eliaz I. The use of biomarker and therapeutic target galectin-3 in integrative oncology: A clinical model of individualized treatment. Poster Session: 11th International Conference of the Society for Integrative Oncology. Houston, TX. Oct. 2014.
  25. Sliva D, Cheng S, Castillo V, Eliaz I. Integrative botanicals in the treatment of cancer: Purified compounds vs. whole herbal preparations. Poster Session: 11th International Conference of the Society for Integrative Oncology. Houston, TX. Oct. 2014.
  26. Eliaz I, McKee D. Galectin-3 as an oncological biomarker. Natural Medicine Journal. 2014 Sept; 6(9).
  27. Cheng S, Welty M, Elia I, Castillo V Sliva D. Honokiol inhibits growth and migration of renal carcinoma. Poster Session, American Association for Cancer Research. San Diego, CA. Apr- 2014.
  28. Eliaz I. An integrative approach to enhancing cognition and executive brain function: A personal perspective. Alternative and Complementary Therapies. 2014 Feb; 20(1): 27-30.
  29. Eliaz I. Human microbiome and nutrition: Untapped clinical potential awaits. Altern Ther Health Med. 2014 Jan;20(S1):58-60.
  30. Eliaz I. The role of galectin-3 as a marker of cancer and inflammation in a stage IV ovarian cancer patient with underlying pro-inflammatory comorbidities. Case Rep Oncol 2013;6:343-349.
  31. Eliaz I. Honokiol Research Review. Natural Medicine Journal. 2013 July; (5)7.
  32. Eliaz I. Cheng, S., Eliaz, I., Lin, J., Sliva, D. Triterpenes from Poria cocos suppress growth and invasiveness of pancreatic cancer cells through the downregulation of MMP-7. Int J Oncol. 2013 Jun;42(6):1869-74.
  33. Cheng S, lin JF, Eliaz I, Sliva D. Triterpenes from mushroom Poria cocos inhibit growth and invasiveness of pancreatic cancer cells. Poster Session: American Association for Cancer Research. Washington, DC. Apr. 2013.
  34. Eliaz I. Modified citrus pectin and galectin-3 and their role in health and illness. Anti-Aging Therapeutics. Volume 14, 2012: Chapter 10, p. 69-78.
  35. Eliaz I. Cold and flu: a pound of prevention. Occup Health Saf. 2012 Nov;81(11):40-42.
  36. Eliaz I, Fritz,H. Galectin-3: An emerging treatment target; role of MCP. IHP. 2012 Sept:52-57.
  37. Jiang J, Thyagarajan-Sahu A, Loganathan J, Eliaz I, Terry C, Sandusky GE, Sliva D. BreastDefend prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer. 2012 Oncol Rep 28:1139-1145.
  38. Jiang J, Eliaz I, Sliva D. Synergistic and additive effects of modified citrus pectin with two novel poly botanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells. Integr Cancer Ther. 2013;12:145-152.
  39. Jiang J, Thyagarajan-Sahu1A, Loganathan J, Eliaz I, Terry C, Sandusky G.E, Sliva, D. BreastDefend suppresses growth and breast-to-lung cancer metastasis in an orthotopic model of human breast cancer. Poster Session, American Association for Cancer Research. Chicago, IL. Apr-May 2012.
  40. Jiang J, Loganathan J, Eliaz I, Terry C., Sandusky G.E., Sliva D. ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer. Int J Oncol. 2012 May;40(5): 1675-1682.
  41. Eliaz I. Stay healthy on the job this cold & flu season. Occup Health Saf. 2011 Nov;80(11):36-8.
  42. Eliaz I. A new breakthrough on modified citrus pectin and the role of galectin-3 in health & disease. Poster Session, 8th International Conference of the Society for Integrative Oncology. Cleveland, OH, Nov 2011.
  43. Eliaz I. Integrative medicine and the role of modified citrus pectin and poly botanicals in cancer prevention and treatment. Intern. J. Mol. Med. 2011, 28 (sup. 1), 176 (S23).
  44. Ramachandran C, Wilk BJ, Hotchkiss A, Chau H, Eliaz I, Melnick SJ. Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. BMC Complem. Altern. Med. 2011, 11:59.
  45. Jiang J, Eliaz E, Sliva D. Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid: Mechanism of activity. Intern. J Oncol. 2011 Jun;38(6):1675-82.
  46. Eliaz I, Yan J, Katz A, Wojnowski R, Jaing J, Jedinak A, Sliva D, Wilk B. The role and synergistic effects of modified citrus pectin & poly botanical formulas in the fight against cancer. Poster Session, Jerusalem International Conference on Integrative Medicine. Jerusalem, Israel, Oct. 2010.
  47. Hotchkiss AT, Rastall R, Gibson G, Eliaz I, Liu LS, Fishman M. 2009. New bioactive and biobased product applications of pectin. Book Chapter in Pectins and Pectinases. H. A. Schols, R. G. F. Visser, A. G. J. Voragen (Eds.), Wageningen Academic Publisher, Wageningen, The Netherlands, pp. 305-312.
  48. Zhao ZY, Liang L, Fan X, Yu Z, Hotchkiss AT, Wilk BJ, Eliaz I. The role of modified citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels. Altern Ther Health Med. 2008 July/Aug; 14(4): 34-38.
  49. Eliaz I, Weil E, Wilk B. Integrative medicine and the role of modified citrus pectin/alginates in heavy metal chelation and detoxification – five case reports. Forsch Komplementarmed. 2007 Dec; 14 (6): 358-364.
  50. Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excretion of toxic metals. Phytotherapy Research. 2006; 20: 859–864.
  51. Eliaz I, Gaurdino J, Hughes K. The health benefits of modified citrus pectin: in Patil BS, Brodbelt JS, Miller EG, and Turner ND (ed.): Potential Health Benefits of Citrus. ACS Symposium Series 936. Oxford University Press. 2006: Chapter 15, p.199-210.
  52. Eliaz I. Modified citrus pectin decreases the total body burden of mercury: A pilot human clinical trial. 228th ACS National Meeting, Philadelphia, PA. August 2004.
  53. Eliaz I, Rosenbaum M. The role of padma basic, a tibetan based herbal formula, in circulatory and cardiovascular disease. Townsend Letter for Doctors and Patients, Aug. – Sept. 2003.
  54. Eliaz I, Rode D. The effect of modified citrus pectin on the urinary excretion of toxic elements. Poster Session, Fifth Annual Conference of Environmental Health Scientists: Nutritional Toxicology and Metabolomic, University of California, Davis. Aug. 2003.
  55. Eliaz I. The role of modified citrus pectin in the prevention of cancer metastasis, Clinical Practice of Alternative Medicine, Volume 2, Number 3, Fall 2001.
  56. Eliaz I. Integrative medicine and prostate cancer, Clinical Practice of Alternative Medicine, Volume 2, Number 3, Fall 2001.
  57. Geller J, Barken I, Eliaz I. The effects of two soy preparations on PSA levels in patients with prostate cancer and the correlation of PSA changes with plasma genistein. Poster Session, Third International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, Nov. 1999.
  58. Eliaz I. The role of modified citrus pectin in the prevention of cancer metastasis; Townsend Letter for Doctors and Patients, July 1999.
  59. Strum S, Scholz M, McDermed J, McCulloch M, Eliaz I. Modified citrus pectin slows PSA doubling time: A pilot clinical trial. Poster Session, International Conference on Diet and Prevention of Cancer, Tampere, Finland, May 1999.
  60. Weiss T, McCulloch M, Eliaz I. Modified citrus pectin induces cytotoxicity in co-cultures with human endothelial monolayers. Poster Session, International Conference on Diet and Prevention of Cancer, Tampere, Finland, May 1999.
  61. Eliaz I. Conversion to terminal melanized hair with a 7.5% herbal preparation: A double blind study. Oral Presentation, Society of Cosmetic Chemists, Annual Scientific Seminar, Chicago, May 6-7, 1999.
  62. Katz M, Eliaz I, Greenberg J. Conversion of vellous hair to terminal hair and remelanization – double blind clinical trial. Poster Session, American Academy of Dermatology, March 1999 Annual Meeting, New Orleans.
  63. Eliaz I. The role of modified citrus pectin in inhibition of cancer metastasis. Explore! Volume 9, Oct. 1998.
  64. Greenberg J, Katz M, Eliaz I. Treatment of androgenetic alopecia with HairPrime – a 7.5% herbal extract; Townsend Letter for Doctors and Patients, Nov. 1996, 68-72.
  65. Eliaz I, Drucker Y. Teeth marks on the tongue, the oriental point of view. American Academy of Dermatology, Oct. 1989; 21.4, I, 817-818.
  66. Greenberg J, Katz M, Eliaz I. Treatment of androgenetic alopecia with a 7.5% herbal extract – double blind clinical trial. Poster Session, American Academy of Dermatology Annual Meeting, New Orleans, Feb. 1996.
  1. Khan A. Case report of long term complete remission of metastatic renal squamous cell carcinoma after palliative radiotherapy and adjuvant dichloroacetate. Advances in Cancer: Research & Treatment. 2012 Vol. 2012, Article ID 441895, DOI: 10.5171/2012.441895.
  2. Jiang J, Wojnowski R, Jedinak A, Sliva D. Suppression of proliferation and invasive behavior of human metastatic breast cancer cells by dietary supplement BreastDefend. Integr Cancer Ther. 2011 Jun;10(2):192-200.
  3. Jiang J, Sliva D. Novel medicinal mushroom blend suppresses growth and invasiveness of human breast cancer cells. Intern. J Oncol. 2010;37:1529-1536.
  4. Yan J, Katz A.E. ProstaCaid induces G2/M cell cycle arrest and apoptosis in human and mouse androgen-dependent and-independent prostate cancer cells. Integr Cancer Ther. 2010 Jun;9(2):186-96.
  5. Yan J, Katz A. PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and- independent prostate cancer cells. Integr Cancer Ther. 2010 Jun;9(2):197-203.
  1. Martínez-Martínez E, Brugnolaro C, Ibarrola J, Ravassa S, Buonafine M, López B, Fernández-Celis A, Querejeta R, Santamaria E, Fernández-Irigoyen J, Rábago G, Moreno MU, Jaisser F, Díez J, González A, López-Andrés N. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension. 2019 Mar;73(3):602-611.
  2. Li HY, Yang S, Li JC, Feng JX. Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity. Biosci Rep. 2018 Dec 18;38(6). pii: BSR20181803.
  3. Merheb R, Abdel-Massih RM, Karam MC. Immunomodulatory effect of natural and modified citrus pectin on cytokine levels in the spleen of BALB/c mice. Int J Biol Macromol. 2018 Oct 3;121:1-5.
  4. Nishikawa H, Liu L, Nakano F, Kawakita F, Kanamaru H, Nakatsuka Y, Okada T, Suzuki H. Modified citrus pectin prevents blood-brain barrier disruption in mouse cubarachnoid hemorrhage by inhibiting galectin-3 2018;0:STROKEAHA.118.021757.
  5. Seely D, Ennis JK, McDonell E, Zhao L. Naturopathic oncology care for thoracic cancers: a practice survey. Integr Cancer Ther. 2018 Sep;17(3):793-805.
  6. Abrams DI. An integrative approach to prostate cancer. J Altern Complement Med. 2018 Sep/Oct;24(9-10):872-880.
  7. Wu KL, Kuo CM, Huang EY, Pan HM, Huang CC, Chen YF, Hsiao CC, Yang KD. Extracellular galectin-3 facilitates colon cancer cell migration and is related to the epidermal growth factor receptor. Am J Transl Res. 2018 Aug 15;10(8):2402-2412. eCollection 2018.
  8. Ibarrola J, Arrieta V, Sádaba R, Martinez-Martinez E, Garcia-Peña A, Alvarez V, Fernández-Celis A, Gainza A, Santamaría E, Fernández-Irigoyen J, Cachofeiro V, Zalba G, Fay R, Rossignol P, López-Andrés N. Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage. Clin Sci (Lond). 2018 Jul 18;132(13):1471-1485.
  9. Tan H, Chen W, Liu Q, Yang G, Li K. Pectin oligosaccharides ameliorate colon cancer by regulating oxidative stress- and inflammation-activated signaling pathways. Front Immunol. 2018 Jun 27;9:1504.
  10. Fang T, Liu DD, Ning HM, Dan Liu, Sun JY, Huang XJ, Dong Y, Geng MY, Yun SF, Yan J, Huang RM. Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3. Acta Pharmacol Sin. 2018 May 16.
  11. Marín-Royo G, Gallardo I, Martínez-Martínez E, Gutiérrez B, Jurado-López R, López-Andrés N, Gutiérrez-Tenorio J, Rial E, Bartolomé MAV, Nieto ML, Cachofeiro V. Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity. Dis Model Mech. 2018 Feb 5;11(2). pii: dmm032086.
  12. Martínez-Martínez E, Ibarrola J, Fernández-Celis A, Calvier L, Leroy C, Cachofeiro V, Rossignol P, López-Andrés N. Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats. J Hypertens. 2018 Feb;36(2):368-376.
  13. Fernandez-García CE, Tarin C, Roldan-Montero R, Martinez-Lopez D, Torres-Fonseca M, Lindhot JS, Vega de Ceniga M, Egido J, Lopez-Andres N, Blanco-Colio LM, Martín-Ventura JL. Increased galectin-3 levels are associated with abdominal aortic aneurysm progression and inhibition of galectin-3 decreases elastase-induced AAA development. Clin Sci (Lond). 2017 Nov 6;131(22):2707-2719.
  14. Shen L, Zhang F, Huang R, Yan J, Shen B. Honokiol inhibits bladder cancer cell invasion through repressing SRC-3 expression and epithelial-mesenchymal transition. Oncol Lett. 2017 Oct;14(4):4294-4300. doi: 10.3892/ol.2017.6665. Epub 2017 Jul 25.
  15. Ried K, Eng P, Sali A. Screening for circulating tumour cells allows early detection of cancer and monitoring of treatment effectiveness: an observational study. Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2275-2285.
  16. Ibarrola J, Martínez-Martínez E, Sádaba JR, Arrieta V, García-Peña A, Álvarez V, Fernández-Celis A, Gainza A, Rossignol P, Cachofeiro Ramos V, López-Andrés N. Beneficial effects of galectin-3 blockade in vascular and aortic valve alterations in an experimental pressure overload model. Int J Mol Sci. 2017 Jul 31;18(8). pii: E1664. doi:
  17. Lu Y, Zhang M, Zhao P, Jia M, Liu B, Jia Q, Guo J, Dou L, Li J. Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice. Mol Med Rep. 2017 Jul;16(1):647-653. doi: 10.3892/mmr.2017.6646. Epub 2017 May 29.
  18. Arrieta V, Martinez-Martinez E, Ibarrola J, Alvarez V, Sádaba R, Garcia-Peña A, Fernández-Celis A, Cachofeiro V, Rossignol P, López-Andrés N. A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis. Clin Sci (Lond). 2017 May 1;131(10):935-949.
  19. Dahdouh E, El-Khatib S, Baydoun E, Abdel-Massih RM. Additive effect of MCP in combination with cefotaxime against Staphylococcus aureus. Med Chem. 2017;13(7):682-688.
  20. Martinez-Martinez E, Ibarrola J, Calvier L, Fernandez-Celis A, Leroy C, Cachofeiro V, Rossignol P, Lopez-Andres N. Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage. PLoS One. 2016 Nov 9;11(11):e0166272.
  21. Sádaba JR, Martínez-Martínez E, Arrieta V, Álvarez V, Fernández-Celis A, Ibarrola J, Melero A, Rossignol P, Cachofeiro V, López-Andrés N. Role for galectin-3 in calcific aortic valve stenosis. J Am Heart Assoc. 2016 Nov 4;5(11). pii: e004360.
  22. Martínez-Martínez E, Calvier L, Rossignol P, Rousseau E, Fernández-Celis A, Jurado-López R, Laville M, Cachofeiro V, López-Andrés N. Galectin-3 inhibition prevents adipose tissue remodelling in obesity. Int J Obes (Lond). 2016 Jun;40(6):1034-8.
  23. Abu-Elsaad NM, Elkashef WF. Modified citrus pectin stops progression of liver fibrosis by inhibiting galectin-3 and inducing apoptosis of stellate cells. Can J Physiol Pharmacol. 2016 May;94(5):554-62.
  24. Vergaro G, Prud’homme M, Fazal L, Merval R, Passino C, Emdin M, Samuel JL, Cohen Solal A, Delcayre C. Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension. 2016 Mar;67(3):606-12.
  25. Ma Z, Han Q, Wang X, Ai Z, Zheng Y. Galectin-3 inhibition is associated with neuropathic pain attenuation after peripheral nerve injury. PLoS One. 2016 Feb 12;11(2):e0148792.
  26. Martínez-Martínez E, López-Ándres N, Jurado-López R, Rousseau E, Bartolomé MV, Fernández-Celis A, Rossignol P, Islas F, Antequera A, Prieto S, Luaces M, Cachofeiro V. Galectin-3 participates in cardiovascular remodeling associated with obesity. Hypertension. 2015 Nov;66(5):961-9.
  27. Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, Jaisser F, Zannad F, Rossignol P, Cachofeiro V, López-Andrés N. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. 2015 Oct;66(4):767-75.
  28. Odun-Ayo F, Mellem J, Naicker T, Reddy L. Chemoprevention of azoxymethane-induced colonic carcinogenesis in Balb/c mice using a modified pectin alginate probiotic. Anticancer Res. 2015 Sep;35(9):4765-75.
  29. Arad U, Madar-Balakirski N, Angel-Korman A, Amir S, Tzadok S, Segal O, Menachem A, Gold A, Elkayam O, Caspi D. Galectin-3 is a sensor-regulator of toll-like receptor pathways in synovial fibroblasts. Cytokine. 2015 May;73(1):30-5.
  30. Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P, López-Andrés N. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 2015 Jan;3(1):59-67.
  31. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):67-75.
  32. Hossein G, Keshavarz M, Ahmadi S, Naderi N. Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of Galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev. 2013;14(12):7561-8.
  33. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One. 2011 Apr 8;6(4):e18683.
  34. Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J Gastroenterol. 2008 Dec 28;14(48):7386-91.
2012-present Semi-annual Meditation and Healing retreats in Israel, 4-9 days each. Total of 1,500 participants.
Feb 2018 Lecture: Meditative Minds – Open Heart: Enhancing Healing Capacity for Practitioners. Integrative Healthcare Symposium (IHS). New York, NY.
Feb 2018 Lecture: Galectin-3, a Conductor in the Cancer Driving Orchestra: Its role in inflammation, fibrosis, metabolic pathways & immunity. Oncology Association of Naturopathic Physicians (OncANP.) Tempe, AZ.
Oct 2017 Lecture: Addressing Galectin-3, the Conductor of Inflammation, Fibrosis, and Cancer. Nevada Homeopathic and Integrated Medical Association (NHIMA). Reno, NV.
May 2017 Lecture: The Role of Galectin-3 Removal in Inflammatory and Fibrotic Diseases. The 11th International Society For Apheresis (ISFA) Congress. Copenhagen, Denmark.
Mar. 2017 Lecture: Innovative Therapies and Compounds in the Treatment of Cancer. 11th Annual Complementary & Alternative Cancer Therapies Conference. West Palm Beach, FL.
Jan. 2017 Webinar: In-Depth Detoxification: An Integrative Approach. Hosted by Better Health Publishing.
Nov. 2016 Webinar: Innovative Approaches to Lyme Disease. Hosted by Better Health Publishing.
Nov. 2016 Poster Presentation: Enhanced Effects of Artemisia annua Derivatives, International Lyme and Associated Diseases Society (ILADS) Conference, Philadelphia, PA.
Oct. 2016 Webinar: Clinically Research Solution to Detox: Beyond Phase 1 & 2. Hosted by Better Health Publishing.
Sep. 2016 Webinar: Optimizing Integrative Oncology: A Comprehensive Model for Individualized Cancer Treatment. Hosted by Better Health Publishing.
Sep. 2016 Lecture: Galectin-3: A Master Modulator of Risk for Cardiovascular Disease, Cancer, Inflammation & Fibrosis. ACAM 2016. Tucson, AZ.
Sep. 2016 Lecture: Modified Citrus Pectin In The Prevention, Control & Spread of Cancer. 44th Annual Cancer Convention, Cancer Control Society. Universal City, CA.
July 2016 Webinar: Galectin-3: The Aging Biomarker. Hosted by Better Health Publishing.
May 2016 Lecture: Optimizing Integrative Oncology: A Comprehensive Model for Individualized Treatment. 14th Annual International Integrative Oncology Conference. San Diego, CA.
Mar. 2016 Lecture: Galectin-3 Removal by Apheresis: Significance and Clinical Applications. UCSD Frontiers in Apheresis. San Diego, CA.
Feb. 2016 Lecture: Targeting Inflammation and Growth Factors in Cancer Treatment with Botanicals and Therapeutic Apheresis. 10th Annual Complementary & Alternative Cancer Therapies Conference. West Palm Beach, FL.
May 2015 Lecture: An ex vivo Clinical Study Demonstrates Lipoprotein Apheresis Reduces Levels of Circulating Galectin-3. American Society for Apheresis (ASFA), San Antonio, TX.
May 2015 Lecture: Apheresis Can Reduce Circulating Levels of the Cancer and Inflammation Promoting Factors Galectin-3 and Vascular Endothelial Growth Factor in Humans. International Society For Apheresis (ISFA). Cuncun, MX.
Nov. 2014 Lecture: Smart Life Forum/Silicon Valley Health Institute, Palo Alto, CA. – Fighting Cancer Metastasis and Heavy Metal Toxicities with Modified Citrus Pectin.
Nov. 2014 Workshop: Meditation and Healing Retreat, Yehiam, Israel.
Aug. 2014 Lecture: Redwood Regional Oncology Center, Santa Rosa, CA – Principles of Integrative Oncology.
July 2014 Workshop: Meditation, Transformation and Healing Retreat, Santa Rosa, CA.
Mar. 2014 Workshop: Meditation and Healing Retreat, Emek Hefer, Israel.
Nov. 2013 Keynote Address: 2013 NDO Naturopathic Conference Ontario, Canada. – A New Paradigm in Anti-Aging Medicine: Addressing Galectin-3 in Cancer and Chronic Disease.
July 2013 Lecture: 2013 AANP Naturopathic Conference, Keystone, CO. – The Active Role of Biomarker Galectin-3 in Cancer, Heart Disease, Inflammation and Fibrosis.
Feb. 2013 Lecture: 2013 OncANP Naturopathic Oncology Conference, Phoenix, AZ. – Honokiol Review.
Feb. 2013 Workshop: Meditation, Transformation and Healing Retreat, Santa Rosa, CA.
Nov. 2012 Webinar: Santa Rosa, CA. – Principles of Integrative Oncology.
Nov. 2012 Webinar: Santa Rosa, CA. – How Your Gums Can Cause Cancer: Understanding the Oral/Systemic Connection.
Nov. 2012 Workshop: Meditation, Transformation and Healing – Meditation Retreat Seminar, Tel Aviv, Israel.
Sept. 2012 Workshop: Meditation, Transformation and Healing – Meditation Retreat Seminar, Santa Rosa, CA.
Aug. 2012 Lecture: 244th ACS National Meeting & Exposition, Philadelphia, PA – Galectin-3 and the Role of Modified Citrus Pectin in Health and Disease.
Jun. 2012 Lecture: Second International Congress on Complementary Oncology, Munich, Germany – Galectin-3 and the Role of Modified Citrus Pectin in Cancer and Beyond.
Jun. 2012 Lecture: Second International Congress on Complementary Oncology, Munich, Germany – Integrative Approaches to Prostate Cancer.
April 2012 The American Academy of Anti-Aging Medicine (A4M) Fellowship in Integrative Cancer Therapies, Phoenix, AZ – Principles of Integrative Oncology: Evaluation of Cancer Risk, and Strategies for Prevention.
Feb. 2012 Lecture: 2012 OncANP Naturopathic Oncology Conference, Phoenix, Arizona – Galectin-3 and the Role of Modified Citrus Pectin and Botanicals in Integrative Oncology.
Dec. 2011 Keynote Address: A4M, 19th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies, Las Vegas, NV –A New Breakthrough on Modified Citrus Pectin and Galectin-3 and their Roles in Health and Illness.
Nov. 2011 Lecture: Ontario Association of Naturopathic Doctors Convention 2011, Toronto, Canada – Modified Citrus Pectin and Polybotanicals – Integrative Breakthroughs in Cancer Treatment.
Nov. 2011 Workshop: 8th International Conference of the Society for Integrative Oncology, Cleveland, OH – Meditation and Healing – Finding an Open Heart in Integrative Oncology.
Oct. 2011 Lecture: Baden Baden Medical Conference, Baden Baden, Germany – Galectin-3 and the Role of Modified Citrus Pectin and Beyond.
Oct. 2011 16th World Congress on Advances in Oncology and 14th International Symposium on Molecular Medicine, Rhodes, Greece – Co-Chair: Molecular Oncology/Cancer Prevention Session– Integrative Medicine and the Role of Modified Citrus Pectin and Poly Botanicals in Cancer Treatment and Prevention.
Sept. 2011 Lecture: 39th Annual Cancer Control Society Convention, Los Angeles, CA. Lecture: Modified Citrus Pectin in the Prevention, Control and Spread of Cancer.
Sept. 2011 Keynote Address.2011 Tiger Lily Foundation 3rd Annual Young Women’s Breast Health Day on Capitol Hill and Congressional Reception, Washington, DC.
Sept. 2011 Meditation Retreat Seminar, Petaluma, CA – Meditation, Transformation and Healing.
Sept. 2011 A4M, Fellowship in Integrative Cancer Therapies, Dallas, TX – Meditation and Healing: Finding an Open Heart in Integrative Oncology.
June 2011 A4M, Fellowship in Integrative Cancer Therapies, Las Vegas, NV- Integrative Approaches to Cancer Therapy.
March 2011 A4M, Fellowship in Integrative Cancer Therapies, Boca Raton, FL- Integrative Approaches to Prostate Cancer.
Oct. 2010 Jerusalem International Conference on Integrative Medicine, Jerusalem, Israel- The Role & Synergistic Effects of Modified Citrus Pectin & Poly Botanical Formulas in the Fight Against Cancer.
Oct. 2010 Jerusalem International Conference on Integrative Medicine, Jerusalem, Israel- Integrative Approaches to Mediation and Healing.
Dec. 2010 A4M, 18th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies, Las Vegas, NV- Integrative Approaches to Detoxification.
Dec. 2009 A4M, 17th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies, Las Vegas, NV- Integrative Medicine in the prevention and treatment of Prostate Cancer.
Oct. 2007 NANP, Rohnert Park, CA
April 2007 Acupuncture & Integrative Medical College, Berkeley, CA.
Oct. 2006 NANP, Rohnert Park, CA.
May 2006 Health Medical Institute, Lafayette, CA.
April 2006 Acupuncture & Integrative Medical College, Berkeley, CA
Aug. 2005 American Academy of Naturopathic Physicians, Phoenix, AZ.
April 2005 California State Oriental Medical Association Exposition, San Francisco, CA.
April 2005 Heel, Santa Monica, CA.
Mar. 2005 American Chemical Society, San Diego, CA.
Jan. 2005 SCRIPPS, San Diego, CA.
Sept. 2004 California State Oriental Medical Association Exposition, San Francisco, CA.
Aug. 2004 American Chemical Society, Philadelphia, PA.
July, 2004 American Naturopathic Medical Association, Las Vegas, NV.
May 2004 Seminar: Integrative Medicine in the Treatment of Cancer. Five Branches Institute, Santa Cruz, CA.
Jan. 2004 Seminar: Integrative Medicine in the Treatment of Cancer. Gerber Medical Clinic, Reno, NV.
Jan. 2004 Seminar: Integrative Medicine in the Treatment of Cancer. Amitabha Clinic, Sebastopol, CA.
Nov. 2003 Lecture: 2nd International Congress on Tibetan Medicine. In Pursuit of Partnership: Philosophy and Practical Applications for Integration, Washington DC.
Oct. 2003 Seminar: Integrative Medicine in the Treatment of Cancer. Amitabha Clinic, Sebastopol, CA.
Oct. 2003 6th Annual Conference on Integrative Approaches to the Prevention & Treatment of Chronic Diseases & Aging, Nevada Homeopathic & Integrative Medicine Center, Las Vegas, NV.
Sept. 2003 Seminar: Integrative Medicine in the Treatment of Cancer. Calgary, AB. Canada.
Aug. 2003 Lecture: 31st Annual Cancer Convention, Modified Citrus Pectin in the Prevention, Control & Spread of Cancer, Cancer Control Society, Universal City, CA.
May 2003 American College for Advanced Medicine, The Role of Modified Citrus Pectin in Treatment of Prostate Cancer, Washington D.C.
May 2003 Lecture: Ayurvedic Conference in Berkeley, CA: TCM Perspective on Blood.
Sept. 2002 Lecture: Integrative Medicine and Nutritional Updates in Prostate Cancer. Nevada Homeopathic & Integrative Medical Association Annual Conference, Lake Tahoe, NV.
Feb. 2002 Lecture: Nutritional Updates in Immunity and Cancer. Orthomolecular Society Annual Meeting, San Francisco, CA.
May 2001 Lecture: Integrative Medicine in Prostate Cancer The American College of Advancement in Medicine Spring Conference.
May 1999 Lecturer at the Society of Cosmetic Chemists, Annual Scientific Conference – Chicago IL.
Sept. 1997 Lecturer at the American Cancer Society Prostrate Cancer Public Forum, San Diego, CA.
May 1997 Co-Chair and Lecturer at symposium – A Comprehensive Approach to Prostate Cancer, University of California San Francisco.
1996-1997 Seminar Leader and Lecturer at North American and Israel seminar series on an integrated approach to the immune system and other topics in complementary medicine for physicians and health practitioners.
1996-1998 Lecturer at various conferences on cancer and immunity.
1991-1992 Director of one-year course in Traditional Chinese Medicine for Medical Doctors and Licensed Acupuncturists, Marin County, CA.
1988-1989 Creator and Director of the Alternative Medicine Project, Hebrew University of Jerusalem, Faculty of Agriculture, External Division.
1988-1989 Member of General Teaching Committee; Member of Acupuncture Teaching Committee; designed syllabus, presented primary lectures and administered the examinations.
1982-1989 Director and Teacher for health professionals and public courses in shiatsu, yoga and yoga therapy.
  • American Society of Clinical Oncology (ASCO)
  • American Association for Cancer Research (AACR)
  • American Society for Apheresis (ASFA)
  • International Society for Apheresis (ISFA)
  • American Chemical Society (ACS)
  • The American Academy of Anti-Aging Medicine (A4M)
  • Society for Integrative Oncology (SIO)
  • U.S. Patent #10213462 – Galectin-3 plasmapheresis therapy
  • U.S. Patent #9549953 – Galectin-3 plasmapheresis therapy
  • U.S. Patent #9649329 – Binding of galectin-3 by low molecular weight pectin to reduce fibrosis
  • U.S. Patent #9427449 – Binding of galectin-3 by low molecular weight pectin to reduce inflammation
  • U.S. Patent #8916541 – Synergistic combination of honokiol and modified citrus pectin in cancer therapy
  • U.S. Patent #8764695 – Reduction of galectin-3 levels by plasmapheresis
  • U.S. Patent #8426567 – Method for enhancing mammalian immunological function
  • U.S. Patent #7452871 – Composition and methods for treating mammals with modified alginates and modified pectins
  • U.S. Patent #7026302 – Composition and methods for treating mammals with modified alginates and modified pectins
  • U.S. Patent #6462029 – Composition and methods for treating mammals with modified alginates and modified pectins
  • U.S. Patent #6274566 – Methods for treating mammals with modified alginates and pectins
  • U.S. Patent #5874093 – Cosmetic composition containing molecular oxygen
  • U.S. Patent #5422100 – Method and product for treating skin afflictions
Aug. 2018 SBIR NIH NIGMS Phase I Grant Award Number R43GM130227. Phase I Project Title: Depleting Circulating Galectin-3 with Therapeutic Apheresis: A Novel Treatment for Sepsis/AKI.

English (fluent), Chinese (basic), Hebrew (fluent), French (basic), Portuguese (fluent), Spanish (limited), Tibetan (limited)

Close

CANCELLATION & REFUND POLICY

You must read and understand our cancellation policy before making a reservation.

Cancellation and refund policies are put in place to ensure the smooth operation of the retreat and to protect the interests of all participants. By making a reservation for this retreat, you acknowledge and agree to the following cancellation policy:

  • On or Before July 1st: Full refund less 10% of your total purchase
  • July 2nd – July 31st: 50% refund of your total purchase
  • On or After August 1st: Non-refundable

Applicable refunds are calculated based on your total purchase, which includes retreat fees and additional nights purchased.

Timely Cancellation Notification: To be eligible for any potential refund, you must notify us of your cancellation at retreats@dreliaz.org and receive an acknowledgment within the timeframe specified in the cancellation policy above. Failure to provide timely notice will result in the forfeiture of your payments.

It is your responsibility to carefully review and understand the cancellation policy before making a reservation. We recommend also considering travel insurance or other forms of coverage to protect yourself against unforeseen circumstances that may require cancellation.

By making a reservation for this retreat, you agree to abide by the cancellation policy and release the organizers, facilitators, and any associated individuals from any liability, claims, or damages arising from cancellation and refund-related matters.

* Please note that the cancellation policy is subject to change at the discretion of the organizers. Any updates or modifications to the policy will be communicated to you in a timely manner.

Close
Retreat Schedule

RETREAT SCHEDULE*

DAY 1: WEDNESDAY, SEPT. 10TH

10:00AM-12:30PM – RETREAT OPENING & TEACHING
12:30PM-2:30PM – LUNCH BREAK
2:30PM-3:15PM – GUIDED HEALING
3:30PM-4:15PM – MOVEMENT CLASS
4:30PM-6:00PM – AFTERNOON TEACHING
6:00PM-6:30PM – SUNSET MEDITATION
6:45PM-8:00PM – DINNER
8:15PM-9:15PM – EVENING TEACHING

DAY 2: THURSDAY, SEPT. 11TH & DAY 3: FRIDAY, SEPT. 12TH

6:30AM-7:00AM – SUNRISE MEDITATION
7:00AM-8:00AM – MORNING TEACHING
8:15AM-9:00AM – BREAKFAST
9:15AM-10:00AM – MOVEMENT CLASS
10:00AM-12:30PM – TEACHING
12:30PM-2:30PM – LUNCH BREAK
2:30PM-3:30PM – HEALING SESSIONS
3:45PM-4:30PM – MOVEMENT CLASS
4:45PM-6:00PM – AFTERNOON TEACHING
6:00PM-6:30PM – SUNSET MEDITATION
6:45PM-8:00PM – DINNER
8:15PM-9:15PM – TEACHING & EVENING MEDITATION

DAY 4: SATURDAY, SEPT 13TH

6:30AM-7:00AM – SUNRISE MEDITATION
7:00AM-8:00AM – MORNING TEACHING
8:15AM-9:00AM – BREAKFAST
9:15AM-10:00AM – MOVEMENT CLASS
10:00AM-12:30PM – TEACHING
12:30PM-2:30PM – LUNCH BREAK
2:30PM-3:15PM – MOVEMENT CLASS
3:30PM-5:00PM – FINAL TEACHING & RETREAT CONCLUSION

*CHANGES MAY APPLY AND UPDATES WILL BE SHARED ACCORDINGLY

Close
Payment plan details

Payment plan consists of 3 installments and includes a $300 upcharge per registrant. The 1st installment is due upon purchase, the 2nd installment will be charged automatically to the card on file 30 days from initial payment and the 3rd installment will be changed 60 days from initial payment.

Payment Plan is available through June 1st.

Please note that the payment plan option is only available for the retreat itself. Any add-ons will be due along with the initial retreat payment and registration.

Payment Plan Breakdown

SINGLE OCCUPANCY
Three installments of $1932 each

SINGLE OCCUPANCY VIP
Three installments of $2765 each

DOUBLE OCCUPANCY
Three installments of $3230 each

DOUBLE OCCUPANCY VIP
Three installments of $4897 each

Close
RATES & FEES
Extended Daily Rate for Add-On Dates to Retreat

* Daily rate is exclusive of taxes and resort experience fee.

Applicable to these dates only (supplies are limited)

Sunday, September 7th
Monday, September 8th
Saturday, September 13th
Sunday, September 14th

Daily Rate Ocean View Room: $499*
>>> VIP Ocean View Suite Package Holders, please reach out to retreat@dreliaz.org to reserve additional nights.

Total Rate: $645.23
Room G.E.T. Tax 4.71% / Room T.A.T. Tax 13.25%

Fees Details
The daily resort experience fee of $48 plus tax includes self-parking, internet access, wellness & cultural classes, shuttle bus service, lei greeting, 1 branded reusable water bottle per registered guest, snorkle rental (one hour/day), and local & domestic long distance calls.